The efficacy and safety of two fixed combinations: timolol-dorzolamide-brimonidine versus timolol-dorzolamide. A prospective, randomized, double-masked, multi-center, 6-month clinical trial.
We compared the efficacy and safety of a new fixed combination of timolol 0.5%/odorzolamide 20%/brimonidine 0.2% in ophthalmic solution versus a fixed combination of timolol 0.5%/dorzolamide 2% in patients with open-angle glaucoma or ocular hypertension. The fixed triple combination was significantly more efficient in mean intraocular pressure reduction from baseline throughout the six-month follow-up.
Baiza-Durán
Leopoldo Martín
LM
Clinical Research Department, Laboratorios Sophia, S.A. de C.V. Guadalajara, Jalisco, Mexico. drbvista@sophia.com.mx
Alvarez-Delgado
Jaime
J
Contreras-Rubio
Angélica Yussett
AY
Medrano-Palafox
Javier
J
De Luca-Brown
Anel
A
Casab-Rueda
Homero
H
Cortés-Gastélum
Marco Antonio
MA
Garcidueñas-Mejía
Miguel Jorge
MJ
Gómez-Bastar
Pedro
P
Gil-Carrasco
Félix
F
Hartleben-Matkin
Curt
C
Jiménez-Román
Jesús
J
Moreno-Marín
Miguel Luis
ML
Paczka-Zapata
José Antonio
JA
Velasco-Gallegos
Gustavo
G
Vergara-Sinta
Mario
M
D000316:Adrenergic alpha-Agonists / Q000008:administration & dosage; D000959:Antihypertensive Agents / Q000008:administration & dosage; D000068438:Brimonidine Tartrate; D002257:Carbonic Anhydrase Inhibitors / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D005260:Female; D005500:Follow-Up Studies; D005902:Glaucoma, Open-Angle / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000188:drug therapy / Q000503:physiopathology; D009883:Ophthalmic Solutions; D011446:Prospective Studies; D011810:Quinoxalines / Q000008:administration & dosage*; D013449:Sulfonamides / Q000008:administration & dosage*; D013876:Thiophenes / Q000008:administration & dosage*; D013997:Time Factors; D013999:Timolol / Q000008:administration & dosage*; D016896:Treatment Outcome
D000316:Adrenergic alpha-Agonists; D000959:Antihypertensive Agents; D002257:Carbonic Anhydrase Inhibitors; D004338:Drug Combinations; D009883:Ophthalmic Solutions; D011810:Quinoxalines; D013449:Sulfonamides; D013876:Thiophenes; D000068438:Brimonidine Tartrate; D013999:Timolol; C062765:dorzolamide